The Hindu·3 min read·medium
Reliance’s Strand Life Sciences gets patent for blood-based early cancer detection
T
The Hindu Bureau
✦AI Summary
Strand Life Sciences, a subsidiary of Reliance Industries, has received an Indian patent for a blood-based early cancer detection platform. The technology uses cell-free DNA analysis and machine learning to identify cancer markers from a simple blood sample.
Strand Life Sciences, Bengaluru-based subsidiary of Reliance Industries Limited, on Tuesday (July 7, 2026) announced the grant of an Indian patent covering its integrated platform for early cancer detection using cell-free DNA (cfDNA) analysis.
healthtechnologybusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in